Evidence map›Paper›PMID 36001419›Full record

ArticleAddiction biology2022

Cortical thickness and related depressive symptoms in early abstinence from chronic methamphetamine use.

Johannes Petzold, Andy C Dean, Jean-Baptiste Pochon, Dara G Ghahremani, Richard De La Garza, Edythe D London

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Addiction biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Johannes PetzoldDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, California, USA.ORCID 0000-0003-4163-9014
Andy C DeanDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, California, USA.ORCID 0000-0003-0172-8848
Jean-Baptiste PochonDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-0629-7779
Dara G GhahremaniDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, California, USA.ORCID 0000-0001-6731-6817
Richard De La GarzaDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, California, USA.ORCID 0000-0003-1943-4469
Edythe D LondonDepartment of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, California, USA.ORCID 0000-0003-3577-7808
University of California, Los Angeles · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
YALE CENTER FOR THE: LEARNING &ATTENTIONP41RR013642 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIN, JACK J · 1998 to 2011
$21.9M
UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural FunctionR01DA045162 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK, MOONEY, LARISSA JEANETTE · 2018 to 2022
$3.3M
NEUROCHEMISTRY OF MODAFINIL-MA INTERACTION IN RAT BRAINP20DA022539 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK · 2006 to 2009
$2.9M
Neural Substrates of Cigarette Craving, Withdrawal, and Relief: Male-Female DifferencesR37DA044467 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK · 2017 to 2022
$2.7M
Aerobic Exercise to Improve Outcomes of Treatment for Methamphetamine DependenceR01DA027633 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAWSON, RICHARD A · 2009 to 2014
$2.7M
Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use DisorderUG3DA048388 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK · 2019 to 2022
$2.3M
Neural Systems, Inhibitory Control, and Methamphetamine DependenceR01DA020726 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK · 2005 to 2008
$2.0M
Response Inhibition and Dopamine Neurotransmission (RI) (4 of 8)RL1DA024853 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK · 2007 to 2011
$1.7M
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCRR NIH HHS M01 RR000865NCRR NIH HHS P41 RR013642NIDA NIH HHS P20 DA022539NIDA NIH HHS R01 DA014093NIDA NIH HHS R01 DA015179NIDA NIH HHS R01 DA020726NIDA NIH HHS R01 DA027633NIDA NIH HHS R01 DA036487NIDA NIH HHS R01 DA045162NIDA NIH HHS R03 DA052719NIDA NIH HHS R21 DA034928NIDA NIH HHS R21 DA040156NIDA NIH HHS R21 DA040168NIDA NIH HHS R21 DA042347NIDA NIH HHS R37 DA044467NIDA NIH HHS RL1 DA024853NIDA NIH HHS T32 DA024635NIDA NIH HHS UG3 DA048388NIMH NIH HHS R21 MH098668
6 · The paper itself

Abstract

Methamphetamine use is surging globally as a cause of morbidity and mortality. Treatment is typically sought in early abstinence, when craving and depressive symptoms are intense, contributing to relapse and poor outcomes. To advance an understanding of this problem and identify therapeutic targets, we conducted a retrospective analysis of brain structure in 89 adults with Methamphetamine Use Disorder who were in early abstinence and 89 healthy controls. Unlike most prior research, the participants did not significantly differ in age, sex and recent use of alcohol and tobacco (p-values ≥ 0.400). We analysed thickness across the entire cerebral cortex by fitting a general linear model to identify differences between groups. Follow-up regressions were performed to determine whether cortical thickness in regions showing group differences was related to craving, measured on a visual analogue scale, or to the Beck Depression Inventory score. Participants in early methamphetamine abstinence (M ± SD = 22.1 ± 25.6 days) exhibited thinner cortex in clusters within bilateral frontal, parietal, temporal, insular, and right cingulate cortices relative to controls (p-values < 0.001, corrected for multiple comparisons). Unlike craving (β = 0.007, p = 0.947), depressive symptoms were positively correlated with cortical thickness across clusters (β = 0.239, p = 0.030) and with thickness in the anterior cingulate cluster (β = 0.246, p = 0.027) in the methamphetamine-dependent group. Inasmuch as anterior cingulate pathology predicts response to antidepressants for Major Depressive Disorder, cingulate structure may also identify patients with Methamphetamine Use Disorder who can benefit from antidepressant medication.

Indexed as

Major Depressive DisorderMethamphetamineAdultAntidepressive AgentsCerebral CortexDepressionHumansMagnetic Resonance ImagingRetrospective StudiesAntidepressive AgentsMethamphetamineanterior cingulate cortexbrain structurecortical thicknessdepressive symptomsgrey matterMethamphetamine Use Disorder

Identifiers

PMID36001419
PMCPMC9413352
OpenAlexW4285676812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.